Twice-daily radiation linked to better quality of life in lung cancer trial
Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival…
A follow-up study to a previous one found that twice-daily radiation may improve quality of life for lung cancer patients, even though adding immunotherapy did not increase overall survival. The NRG-LU005 trial evaluated atezolizumab (Tecentriq) alongside standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer.
Although the study showed no benefit in overall survival with atezolizumab, a subset analysis revealed that patients receiving twice-daily radiation experienced less long-term decline in quality of life compared to those who received once-daily radiation. However, the radiation schedule was not randomized, and the results may be influenced by selection bias, as healthier patients were more likely to complete the patient-reported outcome surveys.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
